Amgen's Kineret Arthritis Product Being Watched By Medco For Cost Impact

Merck-Medco anticipates FDA approval for Amgen's rheumatoid arthritis treatment Kineret as early as the first quarter of 2001. The PBM is keeping close track of development of the drug as one of a handful of R&D projects that could have a significant impact on drug spending when they reach the market.